Location History:
- M.ang.l.o slashed.v, DK (1998 - 2000)
- Maaloev, DK (1999 - 2005)
- Malev, DK (2006)
- Maalov, DK (2009)
- Malov, DK (1998 - 2011)
- MÅløv, DK (2001 - 2014)
- Slagelse, DK (2021)
Company Filing History:
20 out of 1,777 
3 out of 88 
2 out of 832,843 Years Active: 1998-2021
Title: Bernd Peschke: Innovator in Coagulation Research
Introduction
Bernd Peschke, based in Malov, Denmark, is an accomplished inventor with a remarkable portfolio of 25 patents. His contributions to the field of coagulation research have had a significant impact on the treatment of coagulopathies, such as hemophilia.
Latest Patents
Among his latest innovations, Bernd has developed several notable patents including "Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets." This invention describes procoagulant proteins, potentially in the form of fusion proteins or chemical conjugates, alongside methods for their production and specialized polynucleotides. Additionally, he has explored the therapeutic applications of these procoagulant proteins, particularly for individuals suffering from coagulopathies like hemophilia A and B.
Another significant patent is focused on "Conjugated proteins with prolonged in vivo efficacy." This invention pertains to blood coagulation factors, detailing processes for preparing these conjugated proteins by reacting them with a water-insoluble albumin binder in the presence of an optionally substituted cyclodextrin molecule. The therapeutic relevance of these protein conjugates is particularly evident in the prophylactic treatment of hemophilia.
Career Highlights
Bernd Peschke's career has been marked by significant roles in prominent pharmaceutical companies. He has worked at Novo Nordisk A/S and Novo Nordisk Healthcare AG, where he has contributed to advancements in coagulation therapies. His expertise and innovative approach have positioned him as a valuable asset in the field of research and development.
Collaborations
In his professional journey, Bernd has collaborated with notable colleagues, including Michael Ankersen and Thomas Kruse Hansen. Their combined efforts have fostered a rich environment for innovation, driving forward advancements in therapeutic options for blood coagulation disorders.
Conclusion
With a robust portfolio of patents and a career dedicated to improving the lives of those with coagulation disorders, Bernd Peschke stands out as a leading inventor in his field. His continuous efforts in research and development are likely to pave the way for future innovations that will further enhance treatment options for patients worldwide.